TNFα blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis

European Archives of Oto-Rhino-Laryngology

Volumn 263, Issue 7, 2006, Pages 622-626

  Lobo, David ^a   Trinidad, Almudena ^a   García Berrocal, José Ramón ^a   Verdaguer, Jose María ^a   Ramírez Camacho, Rafael ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

6 Methylprednisolone; Etanercept; Experimental labyrinthitis; Guinea pig; Hearing loss

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHYLPREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY THRESHOLD; AUTOIMMUNE DISEASE; CATARACT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIZZINESS; DRUG EFFICACY; EDEMA; EXPERIMENTAL TEST; FEMALE; FRACTURE; GUINEA PIG; HEADACHE; HEARING LOSS; HYPERTENSION; IMMUNOMODULATION; INNER EAR DISEASE; LABYRINTHITIS; LYMPHOMA; MULTIPLE SCLEROSIS; MYELITIS; NONHUMAN; NOSE IRRITATION; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; OSTEOPOROSIS; PAIN; PRIORITY JOURNAL; PRURITUS; STOMACH ULCER; THROAT DISEASE; ANALYSIS OF VARIANCE; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; PERCEPTION DEAFNESS; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; FEMALE; GLUCOCORTICOIDS; GUINEA PIGS; HEARING LOSS, SENSORINEURAL; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LABYRINTHITIS; METHYLPREDNISOLONE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745508532     PISSN: 09374477     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00405-006-0027-9     Document Type: Article

References (25)

1. Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA (2005) An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 65:473-496
2. Botsios C (2005) Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 4:162-170
3. Carvalho GJ, Lalwani AK (1999) The effect of cochleostomy and intracochlear infusion on auditory brain stem response threshold in the guinea pig. Am J Otol 20:87-90
4. García-Berrocal JR, Pinilla Urraca M, Ramirez-Camacho R, González Martin F, López Cortijo C (1995) Patología de oído interno de probable origen autoinmune y su respuesta al tratamiento esteroideo. Acta Otorrinolaring Esp 46:416-420
5. García-Berrocal JR, Vicente J, Arellano B, González FM, Ramírez-Camacho R (1997) Laberintitis experimental autoimmune: evaluación de diversos modelos en cobayas. Acta Otorrinolaring Esp 48:5-10
6. García-Berrocal JR, Ramírez-Camacho R, Zurita M, Arellano B (2000) Respuesta celular inmune precoz en la laberintitis experimental: Estudio inmunohistoquímico. Acta Otorrinolaring Esp 51:557-561
7. García-Berrocal JR, Ramírez-Camacho R, Trinidad A, Zurita M, de la Fuente R, Lobo D (2004) Controversies and criticisms on designs for experimental autoimmune labyrinthitis. Ann Otol Rhinol Laryngol 113:404-410
8. García-Berrocal JR, Ramírez-Camacho R, Trinidad A, Lobo D (2004) Glucocorticoids: the best therapy for immune-mediated inner ear disease. Curr Topics Steroid Res 4:99-104
9. García-Berrocal JR, Trinidad A, Ramírez-Camacho R, Lobo D, Verdaguer JM, Ibáñez A (2005) Immunologic work-up study for inner ear disorders: looking for a rational strategy. Acta Oto-Laryngol 125:814-818
10. García-Berrocal JR, Ramírez-Camacho R, Lobo D, Trinidad A, Verdaguer JM (2006) Adverse effects of glucocorticoids therapy for inner ear disorders. ORL (in press)
11. Goffe B (2004) Etanercept (Enbrel) - an update. Skin Therap Lett 9:1-4
12. Goycoolea MV (2001) Clinical aspects of round window permeability under normal and pathological conditions. Acta Otolaryngol 121:437-447
13. Harris JP, Weisman MH, Derebery JM, Espeland MA, Gautz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko TK, Rauch SD, Telian SA, Brookhouser PE (2003) Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 290:1875-1883
14. Kahna D, Liebling MR, Louie JS (2003) Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 30:1864-1867
15. Lobo D, García-Berrocal JR, Trinidad A, San Román J, Ramírez-Camacho R (2003) Local alternatives to systemic inner ear therapy. In: 3rd Int Symp Inner Ear Pharmacol. Malaga, Spain
16. Ma C, Billings P, Harris JP, Keithley EM (2000) Characterization of an experimentally induced inner ear immune response. Laryngoscope 110:451-456
17. Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, Rahman MU (2005) Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum 53:337-342
18. McCabe BF (1979) Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 88:585-589
19. Rahman MU, Poe DS, Choi HK (2001) Autoimmune vestibulo-cochlear disorders. Curr Opin Rheumatol 13:184-189
20. Rahman MU, Poe DS, Choi HK (2001) Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol 22:619-624
21. Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM (2002) Tumor necrosis factor-alpha, an initiator, an etanercept, an inhibitor of cochlear inflammation. Laryngoscope 112:1627-1634
22. Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM (2003) Proinflammatory cytokine expression in the endolymphatic sac during inner ear inflammation. JARO 4:139-147
23. Staecker H, Lefebvre PP (2002) Autoimmune sensorineural hearing loss improved by tumor necrosis factor α blockade: a case report. Acta Otolaryngol 122:684-687
24. Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34:34-38
25. Wang X, Truong T, Billings PB, Harris JP, Keithley FM (2003) Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol 24:52-57